Elena Lasorsa
Johnson & Johnson (United States)(US)Johnson & Johnson (Brazil)(BR)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Prostate Cancer Treatment and Research, Epigenetics and DNA Methylation, Lung Cancer Treatments and Mutations, Multiple Myeloma Research and Treatments
Most-Cited Works
- → Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma(2015)435 cited
- → Anaplastic lymphoma kinase in human cancer(2011)134 cited
- → Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer(2013)73 cited
- → Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer(2014)58 cited
- → A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation(2014)47 cited
- → Involvement of Grb2 Adaptor Protein in Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK)-mediated Signaling and Anaplastic Large Cell Lymphoma Growth(2010)40 cited
- → Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 Trispecific T-Cell Redirecting Antibody for the Treatment of B-Cell Non-Hodgkin Lymphoma(2022)24 cited
- → Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies(2015)18 cited
- → Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects(2011)17 cited
- → Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer(2014)14 cited